Bespak Limited

Private Limited Company · Crewe

ActiveUnited KingdomIncorporated 2024Private Limited Company

Financial position

Accounts to 2025-12-31 · GBP · Group accounts

Net assets

—

Cash

—

Turnover

£299,200,000

Profit / loss

£1,400,000

Current assets

—

Creditors < 1 year

—

Equity

£363,900,000

Average employees

Not available

Balance-sheet trend

GBP · consolidated

Financial statements

Selected figures from the best-ranked available filing for each period. Missing values remain unknown.

2 periods

Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts

Reported figures	2025-12-31Group · AI-read	2024-12-31Group · AI-read
Balance sheet
Equity	£363,900,000	£309,200,000
Share capital	£5,100,000	£4,800,000
Retained earnings	£34,500,000	£5,100,000
Profit & loss
Turnover	£299,200,000	£228,500,000
Other operating income	£1,100,000	£400,000
Interest receivable	£2,400,000	£21,300,000
Interest payable	£69,400,000	£40,800,000
Profit / loss	£1,400,000	£5,400,000
Operating costs
Depreciation	£11,300,000	£11,800,000
Amortisation	£23,400,000	£18,200,000
Research & development	£6,100,000	£7,700,000
Source evidence	View filing	View filing

From the accounts

What the accounts for 2025-12-31 say about themselves, read by AI from the scanned filing.

Comparatives: Prior-year figures were restated
Principal activity: The principal activity of the Group is that of a contract development and manufacturing organisation (CDMO) focused on inhalation drug delivery.
What it does: contract development and manufacturing · inhalation drug delivery · pressurised metered-dose inhalers · dry powder inhalers · soft mist inhalers · nasal sprays · device development · component manufacturing · fill-finish · analytical testing (AI keywords)
The year: Following its incorporation on 2 February 2024, Bespak Limited focused on delivering strong financial and operational performance in 2025, through its established device, valve and pMDI filling operations. In addition, Bespak is continuing to invest in its long-term strategy of growth through the green transition.
Outlook: In support of the Group’s future growth strategy, a new assembly machine was installed at the King’s Lynn site, increasing capacity to over 500 million valves. At the Holmes Chapel site, a new pMDI filling line was commissioned to significantly expand production capacity and meet expected customer volume increases, with commercial sales commencing in Q1 2026. The Holmes Chapel site also commenced investment in two additional pMDI Fill-Finish lines to further strengthen capacity and support future demand.
Auditor: Ernst & Young LLP · senior statutory auditor Rachel Wilden
Immediate parent: Roar BidCo AB · Sweden
Ultimate parent: Roar HoldCo AB · Sweden
Ultimate controlling party: Roar HoldCo AB
Accounts: Full accounts
Approved: 2026-05-12, signed by Maria Neeve

Subsidiaries (6)

Bespak Europe Limited · 100% · Bergen Way, Kings Lynn, England, PE30 2JJ · device development, component manufacturing, fill-finish capabilities, and analytical testing
Bespak HC Limited · 100% · London Road, Holmes Chapel, England, CW4 8BE · device development, component manufacturing, fill-finish capabilities, and analytical testing
Bespak Ventures BV · 100% · Basisweg 10, 1043 AP Amsterdam, Netherlands · device development, component manufacturing, fill-finish capabilities, and analytical testing
Resyca 11 BV · 51% · Colosseum 23 7521 PV, Enschede, Overijssel, Netherlands
Resyca BV · 51% · Colosseum 23 7521 PV, Enschede, Overijssel, Netherlands
Rsyca GmbH · 51% · Luise-Ulrich-Strasse 14, 80636, Munich, Germany

Turnover by segment (12)

Products: 269.7 (m) (2025-12-31)
Products: 201.1 (m) (2024-12-31)
Services: 29.5 (m) (2025-12-31)
Services: 27.4 (m) (2024-12-31)
United Kingdom: 50.6 (m) (2025-12-31)
United Kingdom: 37.1 (m) (2024-12-31)
Europe: 171.8 (m) (2025-12-31)
Europe: 136.4 (m) (2024-12-31)
United States: 20.0 (m) (2025-12-31)
United States: 27.3 (m) (2024-12-31)
Rest of World: 56.8 (m) (2025-12-31)
Rest of World: 27.7 (m) (2024-12-31)

Related parties (3)

Recipharm AB · related party · term loan payable · €427.5m (m)
RoarBidco AB · related party · term loan payable · £78.5m (m)
RoarBidco AB · related party · term loan payable · €130.0m (m)

Borrowings (3)

Term loan · from Recipharm AB · €427.5m · floating rate of 3-month Euribor plus a margin of 3.2% · secured on The borrowings facilities are secured by a first charge over the share capital in Bespak Europe Limited and Bespak HC Limited.
Term loan · from RoarBidco AB · £78.5m · SONIA plus a margin of 4.45% · secured on The borrowings facilities are secured by a first charge over the share capital in Bespak Europe Limited and Bespak HC Limited.
Term loan · from RoarBidco AB · €130.0m · 3-month Euribor plus a margin of 2.95% · secured on The borrowings facilities are secured by a first charge over the share capital in Bespak Europe Limited and Bespak HC Limited.

Events after the year end (1)